7310 Federal Register / Vol. 73, No. 26 / Thursday, February 7, 2008 / Notices 

TABLE 6.—MODELED PERCENTAGE DISTRIBUTION OF FOOD SERVINGS CONTAMINATED WITH L. monocytogenes AT TIME

OF CONSUMPTION FOR FOODS THAT DO NOT SUPPORT GROWTH

Food Category 

Median Percentage of Food Servings Contaminated with L. monocytogenes at: 

1 cfu/serving 

(0.01 cfu/ga) 

> 1 - 10 cfu/ 

servingb (> 

0.01-0.1 cfu/g) 

> 10 - 100 cfu/ 

servingc (> 0.1 

- 1 cfu/g) 

100 to 103 cfu/ 

servingd (> 1 - 

10 cfu/g) 

> 103 - 104

cfu/servinge (> 

10 - 100 cfu/g) 

> 104 - 105

cfu/servingf (> 

100 - 1,000 

cfu/g) 

> 105 - 106

cfu/servingg (> 

103 - 104 cfu/ 

g) 

Seafood 

Preserved Fish 0.9 (<0.1, 3.1)h 2.1 (0.1, 8.0) 1.2 (<0.1, 5.8) 0.6 (<0.1, 4.0) 0.2 (<0.1, 2.3) 0.1 (<0.1, 1.2) 0.1 (<0.1, 

<0.7) 

Dairy 

Hard Cheese <0.1 (<0.1, .5) <0.1 (<0.1, 

0.6) 

<0.1 (<0.1, 

0.4) 

<0.1 (<0.1, 

0.2) 

<0.1 (<0.1, 

0.1) 

<0.1 (<0.1, 

<0.1) 

<0.1 (<0.1, 

<0.1) 

Processed Cheese 0.2 (<0.1, 0.6) 0.3 (<0.1, 0.9) 0.1 (<0.1, 0.4) 0.1 (<0.1, 0.2) <0.1 (<0.1, 

0.1) 

<0.1 (<0.1, 

0.1) 

<0.1 (<0.1, 

<0.1) 

Ice Cream/Frozen 

Dairy 

0.1 (<0.1, 0.2) 0.2 (0.1, 0.3) 0.1 (<0.1, 0.1) <0.1 (<0.1, 

<0.1) 

<0.1 (<0.1, 

<0.1) 

<0.1 (<0.1, 

<0.1) 

<0.1 (<0.1, 

<0.1) 

Cultured Milk Products 0.1 (<0.1, 1.1) 0.2 (<0.1, 1.5) 0.1 (<0.1, 0.8) <0.1 (<0.1, 

0.4) 

<0.1 (<0.1, 

0.2) 

<0.1 (<0.1, 

0.1) 

<0.1 (<0.1, 

<0.1) 

Deli-type salads 1.9 (0.7, 3.7) 3.0 (0.9, 5.2) 1.1 (0.3, 1.9) 0.3 (0.1, 0.7) 0.1 (<0.1, 0.2) <0.1 (<0.1, 

0.1) 

<0.1 (<0.1, 

<0.1) 

aAssumes a uniform serving size of 100 g. 

b Includes combined estimates for doses of 3.16 and 10 cfu. 

c Includes combined estimates for doses of 31.6 and 100 cfu. 

d Includes combined estimates for doses of 316 and 1,000 cfu. 

e Includes combined estimates for doses of 3160 and 10,000 cfu. 

f Includes combined estimates for doses of 31,600 and 100,000 cfu. 

g Includes combined estimates for doses of 316,000 and 1,000,000 cfu. 

h Numbers in parentheses denote the 5th and 95th percentile uncertainty levels, respectively. 

Dated: January 23, 2008. 

Margaret O’K. Glavin, 

Associate Commissioner for Regulatory 

Affairs. 

[FR Doc. 08–549 Filed 2–6–08; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

Radiological Devices Panel of the 

Medical Devices Advisory Committee; 

Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). At least one portion of the 

meeting will be closed to the public. 

Name of Committee: Radiological 

Devices Panel of the Medical Devices 

Advisory Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on March 4, 2008, from 8 a.m. to 

5:30 p.m., and March 5, 2008, from 8 

a.m. to 5 p.m. 

Location: Hilton Washington DC 

North/Gaithersburg, Salons A, B, and C, 

620 Perry Pkwy., Gaithersburg, MD. 

Contact Person: Nancy Wersto, Center 

for Devices and Radiological Health 

(HFZ–470), Food and Drug 

Administration, 9200 Corporate Blvd., 

Rockville, MD 20850, 240–276–3666, or 

FDA Advisory Committee Information 

Line, 1–800–741–8138 (301–443–0572 

in the Washington, DC area), code 

3014512526. Please call the Information 

Line for up-to-date information on this 

meeting. A notice in the Federal 

Register about last minute modifications 

that impact a previously announced 

advisory committee meeting cannot 

always be published quickly enough to 

provide timely notice. Therefore, you 

should always check the agency’s Web 

site and call the appropriate advisory 

committee hot line/phone line to learn 

about possible modifications before 

coming to the meeting. 

Agenda: On March 4 and 5, 2008, the 

committee intends to discuss and make 

recommendations about computer aided 

detection and diagnosis (CAD) devices 

for radiological images, e.g., 

mammograms, chest x-rays, and 

computed tomography (CT) images of 

the lungs or colon. There will be a 

general discussion focusing on the 

general methodologies for CAD, 

including how CAD devices are used in 

clinical decision-making, how the 

devices are tested, and the information 

needed to properly assess their safety 

and effectiveness. The general 

discussion will be followed by specific 

discussions related to mammography 

CAD devices, colon CAD devices, and 

lung CAD devices. These discussions 

will include how the different types of 

CAD devices are used and the literature 

published regarding these devices, with 

focus on testing issues related to the 

different devices. 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at http://www.fda.gov/ohrms/ 


jlentini on PROD1PC65 with NOTICES
Federal Register / Vol. 73, No. 26 / Thursday, February 7, 2008 / Notices 7311 

dockets/ac/acmenu.htm, click on the 

year 2008 and scroll down to the 

appropriate advisory committee link. 

Procedure: On March 4, 2008, from 8 

a.m. to 5:30 p.m., and on March 5, 2008, 

from 8:30 a.m. to 5 p.m., the meeting is 

open to the public. Interested persons 

may present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before February 19, 2008. 

Oral presentations from the public will 

be scheduled between approximately 10 

a.m. and 10:30 a.m., and between 3:15 

p.m. and 3:45 p.m. on March 4, 2008, 

and between approximately 9:10 a.m. 

and 9:40 a.m., and between 2:15 p.m. 

and 2:45 p.m. on March 5, 2008. Those 

desiring to make formal oral 

presentations should notify the contact 

person and submit a brief statement of 

the general nature of the evidence or 

arguments they wish to present, the 

names and addresses of proposed 

participants, and an indication of the 

approximate time requested to make 

their presentation on or before February 

11, 2008. Time allotted for each 

presentation may be limited. If the 

number of registrants requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

open public hearing session, FDA may 

conduct a lottery to determine the 

speakers for the scheduled open public 

hearing session. The contact person will 

notify interested persons regarding their 

request to speak by February 12, 2008. 

Closed Presentation of Data: On 

March 5, 2008, from 8 a.m. to 8:30 a.m., 

the meeting will be closed so that the 

committee may receive an update from 

FDA about devices under evaluation 

that may be brought before the 

committee in the near future. This 

portion of the meeting will be closed 

because it involves the discussion and 

review of trade secret and/or 

confidential information (5 U.S.C. 

552b(c)(4)). 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Shirley 

Meeks, Conference Management Staff, at 

240–276–8931, at least 7 days in 

advance of the meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://www.fda.gov/oc/advisory/ 

default.htm for procedures on public 

conduct during advisory committee 

meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: January 28, 2008. 

Randall W. Lutter, 

Deputy Commissioner for Policy. 

[FR Doc. E8–2265 Filed 2–6–08; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Human Genome Research 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Human 

Genome Research Institute Special Emphasis 

Panel, T32 Application. 

Date: March 6, 2008. 

Time: 12 p.m. to 1 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 5635 

Fishers Lane, Bethesda, MD 20892. 

(Telephone Conference Call) 

Contact Person: Rudy O. Pozzatti, PhD, 

Scientific Review Officer, Scientific Review 

Branch, National Human Genome Research 

Institute, 5635 Fishers Lane, Suite 4076, MSC 

9306, Rockville, MD 20852, (301) 402–0838, 

pozzattr@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Nos. 93.172, Human Genome Research, 

National Institutes of Health, HHS) 

January 31, 2008. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 08–520 Filed 2–6–08; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. the grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Initial 

Review Group, Neurological Sciences and 

Disorders B. 

Date: February 28–29, 2008. 

Time: 8 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Admiral Fell Inn, Historic Fell’s 

Point, 888 South Broadway, Baltimore, MD 

21231. 

Contact Person: W. Ernest Lyons, PhD, 

Scientific Review Officer, Scientific Review 

Branch NINDS/NIH/DHHS, Neuroscience 

Center, 6001 Executive Blvd., Suite 3208, 

MSC 9529, Bethesda, MD 20892–9529, 301–

496–4056. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Initial 

Review Group, Neurological Science and 

Disorders K. 

Date: March 3–4, 2008. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Fairmont Washington, DC, 2401 

M Street, NW., Washington, DC 20037. 

Contact Person: Shanta Rajaram, PhD, 

Scientific Review Officer, Division of 

Extramural Research, NIH/NIND/SRB, 

Neuroscience Center, 6601 Executive Blvd., 

Suite 3208, MSC 9529, Bethesda, MD 20852, 

(301) 435–6033, rajarams@mail.nih.gov. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Initial 

Review Group, Neurological Sciences and 

Disorders A. 

Date: March 5–6, 2008. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Portofino Hotel, 260 Portofino 

Way, Redondo Beach, CA 90277. 

Contact Person: Richard D. Crosland, PhD, 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Research, 


jlentini on PROD1PC65 with NOTICES